MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Net Income
Bottom-line profit after all expenses, interest, and taxes.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income remains negative
Q3 FY2026 net income was -$62.42M, compared with -$21.62M a year earlier. Trailing-twelve-month net income was -$145.1M.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$105.1M (-20.8%) for the fiscal year ending Dec 2026, a step up from the -40.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$62.42M-68.3% QoQ
- Last fiscal yearDec 2025
- -$86.97M-40.5% YoY
- LTMSep 2026
- -$145.1M-80.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -188.7% | -91.0% | +97.8 pp |
| 1 year | -40.5% | -20.8% | +19.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (86.97M) USD
- Year-over-year change
- -40.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (86.97M) | -40.5% |
| FY2024 | 2024-12-31 | (61.92M) | -90.2% |
| FY2023 | 2023-12-31 | (32.56M) | -24.6% |
| FY2022 | 2022-12-31 | (26.14M) | — |
Net Income vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -80.3% is the 7th highest of 8, against a peer median of +65.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | €890.37M EUR | +482.2% | — | 73.7% | |
| LTM Mar 2026 | $110M USD | +489.6% | — | — | |
| LTM Mar 2026 | $12.01M USD | +126.6% | — | 3.8% | |
| LTM Mar 2026 | -$44.95M USD | +65.1% | — | — | |
| LTM Mar 2026 | -$91.08M USD | -0.9% | — | 253002.8% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | -$145.1M USD | -80.3% | — | — |
KLRAKailera Therapeutics, Inc. | FY2025 | -$148.96M USD | — | — | — |
| LTM Sep 2026 | -$193.81M USD | -0.8% | — | 69.0% | |
| LTM Jun 2026 | -$534.8M USD | -211.7% | — | — | |
| Peer median (excluding MBX) | — | +65.1% | — | 71.4% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 248K |
| Gross Profit | 0 | 0 | 0 | (248K) |
| Gross Margin | — | — | — | — |
| Research & Development | 21.4M | 28.53M | 57.42M | 79.16M |
| Selling, General & Admin | 3.76M | 6.78M | 10.78M | 18.9M |
| Operating Expenses | 25.16M | 35.31M | 68.19M | 98.06M |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| EBITDA | (25.71M) | (32.41M) | (61.68M) | (86.72M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (25.16M) | (35.31M) | (68.19M) | (98.06M) |
| Operating Margin | — | — | — | — |
| Interest Income | 372K | 2.75M | 6.27M | 11.08M |
| Interest Expense | 374K | 0 | 0 | 0 |
| Other Income / Expenses | (974K) | 2.75M | 6.27M | 11.08M |
| Income Before Tax | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.82) | (1.02) | (1.85) | (2.38) |
| EPS (Diluted) | (0.82) | (1.02) | (1.85) | (2.38) |
| Weighted Avg Shares | 31.85M | 31.85M | 33.39M | 36.51M |
| Weighted Avg Shares (Diluted) | 31.85M | 31.85M | 33.39M | 36.51M |
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.